<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659006</url>
  </required_header>
  <id_info>
    <org_study_id>K171201J</org_study_id>
    <nct_id>NCT03659006</nct_id>
  </id_info>
  <brief_title>Identification of Predictive Neuroinflammatory Biomarkers of Neuro-radiological Evolution in Severe Traumatic Brain Injury</brief_title>
  <acronym>ICON-TBI</acronym>
  <official_title>Identification of Predictive Neuroinflammatory Biomarkers of Neuro-radiological Evolution in Severe Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Robert Debré Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tertiary lesions responsible of the neurological decline after severe traumatic brain injury
      (TBI) are partially due to a persistent neuro-inflammation directly modulated by inflammatory
      mediators during the acute phase and detectable by using both multimodal MRI imaging and
      biological biomarkers during the acute phase after traumatic brain injury.

      The main objective is to identify if the level of IL-1beta in cerebrospinal fluid predict in
      a reliable and reproducible way, the neuro-radiological evolution evaluated by the comparison
      of a quantitative MRI performed in post-resuscitation and at one year (quantitative ΔIRM) in
      traumatic brain injuried patients.

      The secondary objectives are:

        -  To understand the links between the acute and chronic neuro-inflammatory phase in a
           population of TBI,

        -  To explore the contribution of the adaptive immune response in the persistent activation
           of the immune response,

        -  To Examine the links between persistent neuroinflammation, clinical deterioration and
           neuroimaging,

        -  To establish a correlation between the pathology and the physio-pathology of TBI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin-1 level in blood predict changes in brain volume assessed by quantitative MRI.</measure>
    <time_frame>Day 42 and 12 months</time_frame>
    <description>Brain volume evolution assessed by quantitative MRI between Day 42 and Day 365</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of biomarkers such as Tau protein and beta-amyloid plaques in serum and cerebrospinal fluid (Aβ1-42, T-tau, and P-tau181P and Interleukin 1)</measure>
    <time_frame>Blood and CSF samples collected at Day1, Day2, Day3, Day5 and Day7</time_frame>
    <description>Plasma and Serum biological collection, multimodal MRI database, clinical database</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Severe Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Biological Collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological Collection</intervention_name>
    <description>Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year</description>
    <arm_group_label>Biological Collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patient ≥ 18 years old at the time of inclusion

          2. Written and informed consent obtained from the family / proxy

          3. Patient hospitalized in neuro-ICU following severe TBI with GCS ≤ 8 at admission

          4. Intubated / ventilated patient scheduled for external ventricular bypass within 24
             hours of hospitalization

          5. Absence of contraindications to perform an MRI

          6. Patient affiliated to a social security scheme (free State medical aid excluded)

        Exclusion Criteria:

          1. Patient under protection of the law (guardianship or tutorship)

          2. TBI of ballistic origin

          3. Pregnant woman

          4. Pre-existing cerebral disease that can bias the MRI scan evaluation

          5. Contraindications to the MRI (pace maker, medical device incompatible with MRI, metal
             plates, ...)

          6. Patient with severe impairment of vital and / or life-threatening function with
             disability prior TBI

          7. Neurological antecedent susceptible to interfere with clinical evolution at one year

          8. Severe cardiogenic shock

          9. Severe respiratory impairment

         10. Extra-brain injuries involving immediate life-threatening

         11. Hemoglobin level below 9g / dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Degos, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent Degos, PU-PH</last_name>
    <phone>01 42 16 37 61</phone>
    <email>vincent.degos@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gregory Torkomian, Master</last_name>
    <phone>01 42 16 37 01</phone>
    <email>gregory.torkomian@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anesthesy department - Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DEGOS Vincent, MD</last_name>
      <phone>0142163761</phone>
      <email>vincent.degos@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>September 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammatory Biomarkers, Traumatic brain injury, multimodal MRI, tertiary lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

